Australia markets open in 9 hours 53 minutes

Molecular Partners AG (MOLN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.50+0.39 (+6.41%)
As of 10:02AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close6.11
Bid0.00 x 0
Ask0.00 x 0
Day's range6.50 - 6.55
52-week range3.32 - 12.70
Avg. volume27,939
Market cap230.598M
Beta (5Y monthly)0.67
PE ratio (TTM)N/A
EPS (TTM)-1.98
Earnings date26 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.06
  • GlobeNewswire

    Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

    ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, announce that the Company will present in a fireside chat at the 2nd TD Cowen Radiopharmaceutical Innovation Summit today, June 17, 2024 at 10:40 a.m. ET (4:40 p.m. CET). Presenting on behalf of Molecular Partners will be Michael Stumpp, Ph.D., Execut

  • GlobeNewswire

    Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

    Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activatorsPreclinical safety, efficacy, and pharmacokinetics support MP0621’s potential to selectively kill cKit-positive cells and conditionally block CD47 with limited systemic side effectsMP0621 presently in IND-enabling studies with Phase 1 in AML anticipated in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursua

  • GlobeNewswire

    Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

    MP0712, a 212Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners’ RDT platform in development in partnership with Orano MedPositive tumor to kidney ratio and biodistribution, favorable antitumor activity and safety profileFirst-in-human study in planning with initial data expected in 2025RDT platform expanding with portfolio of additional targets under evaluation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 11, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement